The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
PreviousPrevious
Volume 356:114 January 11, 2007 Number 2
NextNext

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
by Drazen, J. M.
-Editorial
by Brugarolas, J.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Motzer, R. J.
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. Renal-cell carcinoma of the clear-cell type is particularly important in this regard because of the evidence that mutations in the VHL gene result in stimulation of cellular receptors that promote angiogenesis and tumor growth. This trial found promising results with sunitinib in the treatment of metastatic renal-cell cancer.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.